Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Abstract only LBA3506 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract wil...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 31; no. 15_suppl; p. LBA3506
Main Authors Heinemann, Volker, Fischer von Weikersthal, Ludwig, Decker, Thomas, Kiani, Alexander, Vehling-Kaiser, Ursula, Al-Batran, Salah-Eddin, Heintges, Tobias, Lerchenmueller, Juergen, Kahl, Christoph, Seipelt, Gernot, Kullmann, Frank, Stauch, Martina, Scheithauer, Werner, Hielscher, Joerg, Scholz, Michael, Mueller, Sebastian, Schaefer, Britta, Modest, Dominik Paul, Jung, Andreas, Stintzing, Sebastian
Format Journal Article
LanguageEnglish
Published 20.05.2013
Online AccessGet full text

Cover

More Information
Summary:Abstract only LBA3506 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2013.31.15_suppl.lba3506